Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) SEC filings page on Stock Titan brings together the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents provide structured insight into KalVista’s financial condition, governance, capital structure and key events related to its development and commercialization of EKTERLY (sebetralstat), an oral plasma kallikrein inhibitor for hereditary angioedema (HAE).
Investors can review Form 8‑K current reports in which KalVista announces material events, such as FDA approval of EKTERLY, preliminary and quarterly financial results, appointments of new executives and directors, and the issuance of 3.250% Convertible Senior Notes due 2031. These filings describe terms of financing arrangements, board and committee changes, executive employment agreements and stock‑based inducement awards.
Proxy materials such as the DEF 14A definitive proxy statement detail corporate governance matters, including annual meeting agendas, director elections, advisory votes on executive compensation and auditor ratification. They also outline board structure, committee responsibilities and stockholder voting procedures. Periodic reports referenced in the proxy statement, such as the company’s Annual Report on Form 10‑K, provide audited financial statements and broader business discussion.
Through Stock Titan, users can access these filings as they are made available on EDGAR and use AI‑powered summaries to interpret complex sections, including descriptions of convertible note covenants, events of default, change‑in‑control provisions and compensation arrangements. The filings page is also a key source for tracking any future Forms 3, 4 and 5 that would report insider transactions in KalVista common stock, as well as 10‑Q and 10‑K reports that update on revenue from EKTERLY, research and development spending and liquidity.
By reviewing KalVista’s SEC filings with the help of AI explanations, investors can better understand how the company finances its operations, governs its business and discloses risks and opportunities associated with its rare‑disease portfolio.
Frazier-affiliated funds filed Amendment No. 6 to a Schedule 13D for KalVista Pharmaceuticals (KALV) updating beneficial ownership tables and correcting prior attributions. The filing reports specific share counts held directly by several Frazier vehicles: Frazier Life Sciences Public Fund, L.P. (FLSPF) holds 2,400,276 shares (4.8% of class), Frazier Life Sciences Public Overage Fund, L.P. holds 946,074 shares (1.9%), Frazier Life Sciences X, L.P. holds 1,156,869 shares (2.3%), and Frazier Life Sciences XI, L.P. holds 384,648 shares (0.8%). All percentages are calculated using 49,953,739 shares outstanding as of June 25, 2025 per the issuer's annual report.
The amendment clarifies voting and dispositive power: the reported holdings are shared voting/dispositive power for the listed Frazier entities and correct prior over-attributions to individual committee members or managers. It also states that, except as specified, the prior Schedule 13D and amendments remain unchanged and that the filing does not concede beneficial ownership or group status beyond what is expressly stated. A Joint Filing Agreement is referenced as Exhibit 99.1.
Christopher Yea, Chief Development Officer and director of KalVista Pharmaceuticals (KALV), reported the vesting/settlement of equity awards on 08/17/2025 that resulted in the acquisition of 4,203 shares of common stock, bringing his beneficial ownership to 132,142 shares. A subsequent transaction on 08/18/2025 shows a sale of 2,649 shares at $13.187 per share to satisfy tax withholding obligations related to the vesting. The filing discloses two restricted stock unit grant schedules with periodic vesting: one vesting 1/16th quarterly from August 17, 2022, and another vesting 1/12th quarterly from November 17, 2022. The RSUs/PSUs are contingent rights to receive one share each upon settlement for no consideration.
KalVista Pharmaceuticals insider Form 4: The filing shows Chief Medical Officer Audhya Paul K. received vesting equity and completed a tax-withholding sale. On 08/17/2025 the reporting person was issued 6,446 shares (reported as acquisition via RSU/PSU vesting), bringing beneficial ownership to 119,472 shares. Two RSU entries on 08/17/2025 reflect settlement rights to a total of 6,446 underlying shares at no cash cost. On 08/18/2025 a sale of 2,939 shares occurred at $13.187 per share to satisfy tax withholding, reducing beneficial ownership to 116,533 shares. The sale is described as a routine "sell to cover" for tax obligations.
KalVista Pharmaceuticals (KALV) Chief Executive Officer and Director Benjamin L. Palleiko reported transactions in the company's common stock on August 17-18, 2025. On August 17 he was credited with 9,362 shares as vested restricted/performance stock units; those awards converted into a mix of settled shares and remaining RSU/PSU interests. On August 18 he sold 4,409 shares at $13.187 per share to satisfy tax withholding, leaving beneficial ownership of 374,548 shares of common stock and several outstanding RSU/PSU entitlements.
KalVista Pharmaceuticals insider award disclosure: KalVista reported that Benjamin L. Palleiko, a director and the Chief Executive Officer, received equity awards on 08/11/2025 consisting of 113,920 restricted stock units (RSUs) and an employee stock option covering 113,920 shares with an exercise price of $12.51. The RSUs convert to one share each upon settlement for no consideration, and the RSU vesting schedule provides 1/16th of the RSUs on each quarterly anniversary beginning November 11, 2025, subject to continued service. The option vests over four years beginning September 11, 2025, with 1/48th vesting initially and monthly thereafter, and has an expiration date of 08/10/2035. The reported holdings after these awards are 113,920 RSUs and 113,920 underlying shares from the option, each shown as direct beneficial ownership.
KalVista Pharmaceuticals, Inc. (KALV) – Form 4 insider transaction summary:
- CEO & Director Benjamin L. Palleiko vested 87,500 performance stock units (PSUs) on 07 Jul 2025 after the company met pre-defined performance metrics. Each PSU converted 1:1 into common shares.
- On 09 Jul 2025, Palleiko effected a sale of 32,979 shares at $15.6925 per share. The filing states the sale was solely to satisfy tax-withholding obligations via a “sell-to-cover” mechanism and was not a discretionary trade.
- After the transactions, Palleiko’s direct beneficial ownership stands at 369,595 common shares, a net increase of 54,521 shares versus pre-vesting levels.
The vesting confirms management’s achievement of specified operating or clinical milestones set in January 2023, while the partial sale is procedural. Overall, the filing signals continued insider equity alignment without indicating either bullish or bearish discretionary sentiment.
KalVista Pharmaceuticals (KALV) Form 4: Chief Development Officer Christopher Yea reported two transactions. On 8 July 2025, 60,000 performance stock units (PSUs) vested and converted 1-for-1 into common shares after the company met its performance metrics, raising his direct holdings to 158,189 shares.
On 9 July 2025, Yea executed a Rule 10b5-1 coded S sale of 30,250 shares at an average price of $15.6925 strictly to cover tax-withholding obligations (“sell-to-cover”), leaving him with 127,939 shares.
The net effect is a 29,750-share increase in ownership. No derivative securities were reported. The transactions appear routine and non-discretionary under the company’s equity compensation plan.